Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Interim Management Statement

13 May 2014 07:00

RNS Number : 8370G
Ark Therapeutics Group PLC
13 May 2014
 



 

Ark Therapeutics Group plc

 

Interim Management Statement and Notice of Annual General Meeting

 

13 May 2014 - Ark Therapeutics Group plc ("Ark" or the "Company") today publishes its interim management statement for the period from 1 January 2014 to date.

 

· On 28 March 2014, we were pleased to announce that the Company had signed heads of terms in connection with the possible acquisition of a revenue-generating and profitable UK-based private company in the healthcare support services sector ("Target").

 

The transaction would be structured by way of an acquisition of the Target by Ark in consideration for the issue of new Ark shares to the shareholders of the Target. Due to its size in relation to Ark, the proposed acquisition of the Target would constitute a 'reverse takeover' for the purposes of the Listing Rules.

 

In response to a request by the Company, the UK Listing Authority suspended the listing of Ark's Premium listed shares on the Main Market of the London Stock Exchange on 28 March 2014 pending publication of the required shareholder documents. Shareholder approval would be required to approve the acquisition of the Target which would be sought at a general meeting to be convened in due course, after which the Company would also expect to seek a lifting of the trading suspension. 

 

The Board will make further announcements in due course.

 

· On 30 April 2014, the Company announced its financial results for the year ended 31 December 2013:

 

· Total revenues and other income for the year ended 31 December 2013 of £0.3m (31 December 2012: £1.9m)

 

· Net assets at 31 December 2013 of £0.9m (31 December 2012: net liabilities of £0.2m)

 

· Cash and short-term deposits of £0.8m (31 December 2012: £1.7m)

 

· Profit for the year after tax was £1.1m (31 December 2012: loss after tax was £2.5m)

 

The Company's Annual General Meeting will be held at 2.30 pm on 30 June 2014 at the offices of Ashurst LLP, Broadwalk House, 5 Appold Street, London EC2A 4HA.

 

 

For further information please contact:

 

Ark Therapeutics Group plc

Tel: +44 (0)203 755 5160

 

Iain G Ross, Non-Executive Chairman

 

David Venables, Non-Executive Director

 

 

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding Ark's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond Ark's control that could cause the actual results, performance or achievements of Ark to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Ark's present and future business strategies and the environment in which Ark will operate in the future. These forward-looking statements speak only as at the date of this announcement. Ark expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in Ark's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSGGUWGAUPCGUP
Date   Source Headline
8th Jun 20078:00 amRNSBlocklisting Interim Review
8th Jun 20078:00 amRNSBlocklisting Interim Review
7th Jun 20077:00 amRNSKerraped Launch
31st May 200710:13 amRNSVoting Rights and Capital
31st May 20077:02 amRNSResearch Update
22nd May 20077:01 amRNSTrinam Update
2nd May 20077:01 amRNSTrinam(R) RAC Application
30th Apr 20074:10 pmRNSVoting Rights and Capital
27th Apr 20077:01 amRNSRegulatory Update
26th Apr 20075:29 pmRNSResult of AGM
24th Apr 20077:01 amRNSResearch Update
2nd Apr 20071:42 pmRNSVoting Rights and Capital
2nd Apr 200712:22 pmRNSAnnual Information Update
30th Mar 20071:57 pmRNSHolding(s) in Company
19th Mar 20072:20 pmRNSBlock Listing Application
15th Mar 20075:37 pmRNSHolding(s) in Company
12th Mar 20072:12 pmRNSHolding(s) in Company
7th Mar 20077:01 amRNSFinal Results
5th Mar 20075:33 pmRNSHolding(s) in Company
1st Mar 200710:40 amRNSVoting Rights and Capital
23rd Feb 20079:00 amRNSHolding(s) in Company
22nd Feb 20077:01 amRNSStroke Patent
16th Feb 20079:00 amRNSHolding(s) in Company
16th Feb 20077:00 amRNSResearch Update
6th Feb 20071:03 pmRNSHolding(s) in Company
5th Feb 20072:41 pmRNSOption Awards
1st Feb 20077:01 amRNSEuropean Grant Awarded
25th Jan 20075:19 pmRNSHolding(s) in Company
22nd Jan 200711:24 amRNSTotal Voting Rights
19th Jan 200712:28 pmRNSNotice of Results
15th Jan 200712:45 pmRNSRe: Award
11th Jan 20077:01 amRNSResearch Update
5th Jan 20077:53 amRNSResearch Update
20th Dec 20062:00 pmRNSHolding(s) in Company
20th Dec 200610:28 amRNSVoting and Rights Capital
18th Dec 20067:01 amRNSHolding(s) in Company
14th Dec 20067:01 amRNSPlacing of Shares
4th Dec 200611:26 amRNSBlocklisting Interim Review
4th Dec 200611:21 amRNSBlocklisting Interim Review
27th Nov 20061:44 pmRNSHolding(s) in Company
13th Oct 20067:00 amRNSCerepro Patent Granted
10th Oct 20067:01 amRNSRe: Kerraboot
2nd Oct 20063:49 pmRNSHolding(s) in Company
27th Sep 20067:01 amRNSResearch Update
8th Sep 20064:11 pmRNSHolding(s) in Company
5th Sep 20067:03 amRNSResearch Update
1st Sep 20067:00 amRNSCerepro EMEA review
30th Aug 20067:01 amRNSInterim Results
23rd Aug 20067:01 amRNSResearch Update
4th Aug 200612:50 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.